

Ref. No.: NLL/CS/2025- 494

May 30, 2025

To

National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

To

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Scrip Code: 532649

Sub: Outcome of Board Meeting

Ref.: Regulation 30 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulation").

Dear Sir/ Madam,

We wish to inform you that the Board of Directors in their meeting held on May 30, 2025, have, inter-alia, noted, decided and approved the following matters:

1. Take note of expiry of term of Mr. Puneet Sud (DIN 09735713) as a Wholetime Director, designated as Director (Operations) of the Company on May 31, 2025 (being his last working day);
2. Take note of resignation of Mr. Puneet Sud (DIN 09735713) as a Director of the Company effective from closing hours of May 31, 2025.
3. Appointed Dr. Surulichamy Senthilkumar (DIN 11124083) as an Additional Director from June 01, 2025 till next General Meeting or Postal Ballot process. as well as Wholetime Director designated as Director (R&D) of the Company for a period of three years with effect from June 01, 2025.

The relevant disclosures regarding the above have been enclosed as per **Annexure – A**.

Further, please also be informed that the Audit Committee and Board of Directors could not approve and take on record the Audited Financial Results and Financial Statements for the quarter and year ended March 31, 2025. Therefore, the meetings stand adjourned *sine die*, for said matters. The reasons for delay in submission of financial results is being submitted by way of separate letter.

The date of adjourned Board Meeting shall be intimated in due course of time. The trading window closure period is being extended accordingly till 48 hours after the declaration of Financial Results for the period ended on March 31, 2025.

The Board meeting commenced at 03:00 P.M. and concluded at 03:40 P.M.

Nectar Lifesciences Ltd.



Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer

Encl.: as above.

Annexure-A

Details as required as per LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as amended, are as follows:

Sr. No.	Particulars	Disclosures	
		M. Puneet Sud	Dr. Surulichamy Senthilkumar
1.	Reason for change viz. Appointment, re-appointment, resignation, removal, death or otherwise	Expiry of term as a Wholetime Director and resignation as a Director.	Appointed as an Additional Director as well as Wholetime Director designated as Director (R&D) of the Company
2.	Date of appointment/re-appointment/ cessation (as applicable) & term of appointment/ re-appointment	Expiry of term as a Wholetime Director on May 31, 2025 (being his last working day); Resignation as a Director effective from closing hours of May 31, 2025.	Additional Director with effect from June 01, 2025 till next General Meeting or Postal Ballot process. Wholetime Director for a period of three years with effect from June 01, 2025.
3.	Brief profile (in case of appointment)	Not Applicable ("NA")	Dr. Surulichamy SenthilKumar aged 52 years completed his graduation in Chemistry from the Gandhigram Rural University, Gandhigram, Tamil Nadu, Post-graduation in Chemistry from Bharathidasan University, Tiruchirappalli, Tamil Nadu and a Scholar Ph.D. in Chemistry from Monad University, Hapur, UP. Dr. Kumar has joined the Company on March 21, 2008, as Manager, PD Lab at Unit II, Derabassi, Punjab and elevated to the General Manager (R&D). Dr. Kumar has more than 12.5 years of work experience in Orchid Chemicals and Pharmaceuticals Limited, Chennai.

4.	Disclosure of relationships between directors (in case of appointment of a director)	NA	He does not have any relationship with any director of the Company
5.	Certification of Director/ KMP/ Senior Management as per BSE Circular no. LIST/COMP/14/2018-19 and the NSE Circular no. NSE/ CML/2018/24, both dated 20 June 2018	NA	He has certified and the Company is also affirming that he is not disqualified to become a Director under the Companies Act, 2013 and not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.
6.	Shareholding in the Company	NA	Nil
7.	Certification of Criteria of Independence in case of Independent Director	NA	NA
8.	Letter of Resignation along with detailed reasons for resignation	Attached	NA

May 30, 2025

To,
The Board of Directors
Nectar Lifesciences Limited ("Company")
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali), Punjab

Sub.: Resignation as a Director of the Company

Dear Sirs/ Madams,

As you are aware that my term as a Wholetime Director designated as a Director (Operations) of the Company is being expiring on May 31, 2025. Consequently, I cannot continue a director of the Company as the Company may need to appoint a new Wholetime Director.

Therefore, I am writing to formally resign from my position as Director of the Company as well, with effect from closing hours of May 31, 2025 (being my last working day).

Thank you again for the opportunity to serve as part of the leadership team at the Company. I wish you and the company continued success in the future.

Sincerely,



(Puneet Sud)
Director
Nectar Lifesciences Limited
DIN: 09735713